GUJTHEM
Gujarat Themis Biosyn Limited (GUJTHEM) Stock Analysis
Gujarat Themis Biosyn Limited is an Indian pharmaceutical company producing fermentation-based APIs and biosimilars. It manufactures antibiotics and statin intermediates for global pharma customers. The company operates biotech manufacturing in Gujarat. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹363.50
-4.79% 1W | -9.70% 52W
Market Cap
4.7k CR
P/E Ratio
81.3
52W High
₹479
52W Low
₹225.1
Div. Yield
0.18%
Beta
0.6
50 DMA
₹394.2
200 DMA
₹358.7
Profit Margin
28%
Inst. Own.
3.2%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
| Sales | 36 | 44 | 44 |
| Expenses | 22 | 25 | 23 |
| Operating Profit | 14 | 19 | 21 |
| OPM % | 39% | 44% | 48% |
| Other Income | 0 | 1 | 0 |
| Interest | 0 | 2 | 2 |
| Depreciation | 2 | 4 | 4 |
| Profit before tax | 12 | 14 | 15 |
| Tax % | 25% | 24% | 27% |
| Net Profit | 9 | 11 | 11 |
| EPS in Rs | 0.83 | 1.00 | 1.02 |
| Metric | Mar 2026 |
|---|---|
| Sales | 166 |
| Expenses | 90 |
| Operating Profit | 76 |
| OPM % | 46% |
| Other Income | 2 |
| Interest | 3 |
| Depreciation | 13 |
| Profit before tax | 62 |
| Tax % | 25% |
| Net Profit | 47 |
| EPS in Rs | 4.28 |
| Dividend Payout % | 0% |
Shareholding Pattern
Promoters70.87%
FIIs2.95%
DIIs1.17%
Public25.01%
Promoters70.87%
FIIs1.96%
DIIs1.17%
Public26.00%
Promoters70.86%
FIIs1.80%
DIIs1.17%
Public26.15%
Promoters70.87%
FIIs1.76%
DIIs1.17%
Public26.18%
Promoters59.33%
FIIs4.93%
DIIs13.79%
Public21.95%
Promoters75.00%
FIIs0.01%
DIIs0.03%
Public24.95%
Promoters70.87%
FIIs1.05%
DIIs0.82%
Public27.26%
Promoters70.87%
FIIs1.91%
DIIs1.17%
Public26.05%
Promoters70.86%
FIIs1.80%
DIIs1.17%
Public26.15%
Promoters59.33%
FIIs4.93%
DIIs13.79%
Public21.95%
GUJTHEM
Holdings Analysis
Key strengths & risk signals
58
Overall
52
Fundamental
65
Technical
Risks (4)
Cannot calculate PEG - insufficient growth data.
RECOVERY MODE! Current price (363.5) above 200-day but below 50-day.
NEGATIVE MOMENTUM! Price declined across timeframes - down 4.8% (1 week), 15.6% (1 month), 4.1% (3 months).
WEAK YEAR! Stock declined 9.7% in the last year.
Strengths (4)
EXCELLENT EFFICIENCY! 28.0% profit margin - company keeps strong profits.
BULLISH TREND! 50-day average (394.2) is above 200-day average (358.7) - positive signal.
LOW VOLATILITY! Beta of 0.60 - stable stock, less market risk.
BULLISH SENTIMENT! In last 30 days: 10 up days, 20 down days. Avg volume on up days: 697,612 vs down days: 513,685. Ratio: 1.36x
Fundamental & Technical Analysis
58Overall
52Fundamental
65Technical
Fundamental Breakdown
Growth Quality
7/30
Revenue CAGR: 3.8% (SLOW, 5/15). Profit CAGR: -7.0% (DECLINING, 2/15).
Profit Margin
9/10
EXCELLENT EFFICIENCY! 28.0% profit margin - company keeps strong profits.
PEG Valuation
1/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.18% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 24.95% public ownership - balanced ownership structure.
Stability Index
8/10
GOOD STABILITY! Only 1 revenue dip in history. Strong business fundamentals.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (394.2) is above 200-day average (358.7) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (363.5) above 200-day but below 50-day.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
3/10
WEAK YEAR! Stock declined 9.7% in the last year.
Volume Sentiment
25/30
BULLISH SENTIMENT! In last 30 days: 10 up days, 20 down days. Avg volume on up days: 697,612 vs down days: 513,685. Ratio: 1.36x
RSI
4/5
APPROACHING OVERSOLD! RSI at 37.5 - watch for reversal.
52W Range
3/5
MID RANGE! Trading at 54.5% of 52W range - neutral zone.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 4.8% (1 week), 15.6% (1 month), 4.1% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.60 - stable stock, less market risk.
GUJTHEM
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-08-14 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GUJTHEM | ₹363.50 | 81.3 | 28.0% | 3.8% | -7.0% | -9.7% | 58 | BREAKDOWN | +22.0% | +1.8% | +22.0% | -0.9% |
| RPGLIFE | ₹2,719.20 | 37.6 | 16.3% | 11.3% | 19.4% | +27.6% | 75 | APPROACHING SUPPORT | +17.1% | +3.0% | +15.9% | +10.6% |
| ORCHPHARMA | ₹984.00 | 611.1 | 3.5% | 22.3% | -40.1% | +37.3% | 67 | APPROACHING RESISTANCE | -156.1% | -86.6% | +15.6% | +28.0% |
| GUFICBIO | ₹406.30 | 55.5 | 7.5% | 6.1% | -6.9% | +15.7% | 60 | BREAKDOWN | +70.2% | +1.8% | +16.6% | +3.6% |
| AARTIDRUGS | ₹413.30 | 19.7 | 7.1% | -2.3% | 5.4% | -17.9% | 57 | BOUNCE FROM SUPPORT | -6.9% | -9.1% | +19.0% | -2.4% |
| UNICHEMLAB | ₹531.10 | 12.3 | 13.2% | 18.4% | – | +12.3% | 64 | BREAKDOWN | -495.2% | +280.7% | +20.1% | +10.0% |
| SOLARA | ₹644.40 | – | -0.1% | -1.2% | – | +14.8% | 53 | CONSOLIDATING DOWN | +55.2% | +69.8% | +19.5% | -1.5% |
| INDSWFTLAB | ₹360.90 | 53.9 | 8.5% | -19.7% | -3.2% | +249.6% | 59 | BREAKDOWN | +180.7% | +63.6% | +21.0% | +12.8% |
Data from TradeAlone · Updated daily
GUJTHEM News
Gujarat Themis Biosyn Limited (gujthem) Q1 FY27: Topline Surges 22%, PAT Improves 22%2026-08-07Gujarat Themis Biosyn Limited Announces Strategic Acquisitions and Expansion Plans2026-06-29Gujarat Themis Biosyn Limited (gujthem) Q4 FY26: Strong Revenue Growth, Margin Expansion, and Strategic Acquisitions2026-05-25
